Why the study?
Current clinical trials of mobile-based lifestyle interventions have mainly been conducted in non-elderly populations, leaving a need for well-designed trials among elderly adults who are more susceptible to chronic diseases.
Key points are not available for this paper at this time.
Population
Overweight or obese adults aged 60–80 years in China
Comparison
Mobile-based nutrition and exercise intervention vs mobile-based exercise intervention vs no intervention
Design
Randomized controlled trial protocol
Follow-up
3 months
Mobile interventions promote weight loss in overweight elderly; extends prior RCT evidence from non-elderly to this high-risk group.
Background: Promotion of a healthy lifestyle is considered a good strategy for dealing with chronic diseases. Mobile-based lifestyle interventions have shown beneficial effects in the control and treatment of chronic diseases such as diabetes, obesity and metabolic syndrome. Current clinical trials for mobile-based lifestyle intervention were mainly conducted among non-elderly populations, thus well-designed trials performed among the elderly who are more susceptible to chronic diseases are needed. The study aims to assess the effect of the mobile-based lifestyle intervention on the improvement of body weight, glucose and lipid metabolism among overweight and obese elderly adults in China. Materials and Methods: Participants aged 60–80 years who are overweight or obese will be randomly assigned to receive mobile-based nutrition and exercise intervention, mobile-based exercise intervention and no intervention for 3 months. Before the intervention, participants will receive the training of the mobile application and sports bracelet. The primary outcome will be the between-group (three groups) difference in body mass index at the end of intervention. The secondary outcomes will include body composition, parameters of glucose and lipid metabolism, blood pressure, dietary data and physical activity data. All these outcomes will be assessed at baseline, day 45 and day 90. Ethics and dissemination: The trial has been approved by the Ethics Committee of Peking University Health Science Center (IRB00001052-18039).
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: